2022
Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model
Rabiee A, Deng Y, Ciarleglio M, Chan JL, Pons M, Genesca J, Garcia‐Tsao G. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model. Hepatology Communications 2022, 6: 3324-3334. PMID: 36214066, PMCID: PMC9701481, DOI: 10.1002/hep4.2091.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientSignificant portal hypertensionTransient elastographyNASH cirrhosisPortal hypertensionFibrosis-4 indexPresence of CSPHVenous pressure gradientNonalcoholic steatohepatitis cirrhosisBody mass indexLiver stiffness measurementGood calibrationCompensated cirrhosisFIB-4Mass indexPlatelet countValidation cohortNoninvasive predictorTraining cohortBaseline riskLaboratory valuesCirrhosisHigh riskSeparate cohortNoninvasive surrogate
2013
Seroprevalence of Hepatitis A among Students Enrolled in Tehran University of Medical Sciences during 2011.
Rabiee A, Nikayin S, Hashemi SR, Mohaghegh M, Amini M, Rabiee R, Merat S. Seroprevalence of Hepatitis A among Students Enrolled in Tehran University of Medical Sciences during 2011. Middle East Journal Of Digestive Diseases 2013, 5: 137-40. PMID: 24829683, PMCID: PMC3990182.Peer-Reviewed Original ResearchHepatitis A virusHepatitis ATehran UniversitySeroprevalence of HAVAnti-HAV IgG antibodiesAnti-HAV antibodiesHealth science studentsHigh-risk groupUniversal vaccination strategyMedical SciencesIgG antibodiesVaccination strategiesRisk groupsHealth workersTargeted vaccinationHigh riskGeneral populationSeropositive resultsA virusSimple questionnaireSerum samplesSeroprevalenceVaccinationSerious diseasePrevious reports